ASMB (Assembly Biosciences) Current Accrued Expense: $1.84 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASMB Assembly Biosciences Inc ASMB
31 GF Score
Price $26.61
! 3 Warning Signs
View Full Analysis

What is Assembly Biosciences Current Accrued Expense?

Assembly Biosciences ASMB -0.45% 31 Current Accrued Expense is $1.84 Mil as of Mar. 2026. GuruFocus rates ASMB with a GF Score™ of 31/100. The stock has 3 warning signs investors should review.

Assembly Biosciences's Current Accrued Expense for the quarter that ended in Mar. 2026 was $1.84 Mil.

Assembly Biosciences's quarterly Current Accrued Expense declined from Sep. 2025 ($3.73 Mil) to Dec. 2025 ($2.61 Mil) and declined from Dec. 2025 ($2.61 Mil) to Mar. 2026 ($1.84 Mil).

Assembly Biosciences's annual Current Accrued Expense increased from Dec. 2023 ($1.15 Mil) to Dec. 2024 ($2.66 Mil) but then declined from Dec. 2024 ($2.66 Mil) to Dec. 2025 ($2.61 Mil).

Assembly Biosciences Current Accrued Expense Related Terms

Assembly Biosciences Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Assembly Biosciences's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Assembly Biosciences Current Accrued Expense Chart

Assembly Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.84 4.21 1.15 2.66 2.61

Assembly Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.58 2.06 3.73 2.61 1.84
ASMB
31GF Score
Assembly Biosciences Inc ASMB
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Assembly Biosciences Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $1.84 Mil mean?
Assembly Biosciences (ASMB) has a Current Accrued Expense of $1.84 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Assembly Biosciences and its competitors.
Is Assembly Biosciences' Current Accrued Expense too high?
Assembly Biosciences' current Current Accrued Expense is $1.84 Mil. Overall, Assembly Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' Current Accrued Expense compare to CTNM and PRTA?
Assembly Biosciences' Current Accrued Expense of $1.84 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Assembly Biosciences and its competitors. Assembly Biosciences's current Current Accrued Expense is $1.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Assembly Biosciences (ASMB) has a current Current Accrued Expense of $1.84 Mil. The current Current Accrued Expense is $1.84 Mil. Assembly Biosciences' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Assembly Biosciences (ASMB), the current Current Accrued Expense is $1.84 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Assembly Biosciences Business Description

Other Exchanges V7B:Germany
Address Two Tower Place, 7th Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
31GF Score

Get the complete analysis for ASMB

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.61
Price